[1] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472): 1687-1717.
doi: 10.1016/S0140-6736(05)66544-0
pmid: 15894097
|
[2] |
SINGAL P K, ILISKOVIC N. Doxorubicin-induced cardiomyopathy[J]. N Engl J Med, 1998, 339(13): 900-905.
doi: 10.1056/NEJM199809243391307
|
[3] |
FELKER G M, THOMPSON R E, HARE J M, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy[J]. N Engl J Med, 2000, 342(15): 1077-1084.
doi: 10.1056/NEJM200004133421502
|
[4] |
MANTAWY E M, EL-BAKLY W M, ESMAT A, et al. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis[J]. Eur J Pharmacol, 2014, 728: 107-118.
doi: 10.1016/j.ejphar.2014.01.065
pmid: 24509133
|
[5] |
GUO R M, LIN J C, XU W M, et al. Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells[J]. Int J Mol Med, 2013, 31(3): 644-650.
doi: 10.3892/ijmm.2013.1246
|
[6] |
GUO R M, WU K, CHEN J F, et al. Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells[J]. Cell Physiol Biochem, 2013, 32(6): 1668-1680.
doi: 10.1159/000356602
pmid: 24356372
|
[7] |
ROCCA C, PASQUA T, CERRA M C, et al. Cardiac damage in anthracyclines therapy: focus on oxidative stress and inflammation[J]. Antioxid Redox Signal, 2020, 32(15): 1081-1097.
doi: 10.1089/ars.2020.8016
|
[8] |
TIMM K N, TYLER D J. The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity[J]. Cardiovasc Drugs Ther, 2020, 34(2): 255-269.
doi: 10.1007/s10557-020-06941-x
pmid: 32034646
|
[9] |
CARDINALE D, COLOMBO A, BACCHIANI G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy[J]. Circulation, 2015, 131(22): 1981-1988.
doi: 10.1161/CIRCULATIONAHA.114.013777
pmid: 25948538
|
[10] |
ZAMORANO J L, LANCELLOTTI P, RODRIGUEZ MUÑOZ D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines[J]. Eur J Heart Fail, 2017, 19(1): 9-42.
doi: 10.1002/ejhf.654
|
[11] |
CHENG J, KAMIYA K, KODAMA I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential[J]. Cardiovasc Drug Rev, 2001, 19(2): 152-171.
pmid: 11484068
|
[12] |
DULIN B, ABRAHAM W T. Pharmacology of carvedilol[J]. Am J Cardiol, 2004, 93(9): 3-6.
|
[13] |
GAO G, JIANG S L, GE L L, et al. Atorvastatin improves doxorubicin-induced cardiac dysfunction by modulating Hsp70, Akt, and MAPK signaling pathways[J]. J Cardiovasc Pharmacol, 2019, 73(4): 223-231.
doi: 10.1097/FJC.0000000000000646
pmid: 30540688
|
[14] |
MCMURRAY J J, PACKER M, DESAI A S, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11): 993-1004.
doi: 10.1056/NEJMoa1409077
|
[15] |
XIA Y, CHEN Z W, CHEN A, et al. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy[J]. J Mol Cell Cardiol, 2017, 108: 138-148.
doi: S0022-2828(17)30113-X
pmid: 28623750
|
[16] |
PAN J A, TANG Y, YU J Y, et al. miR-146a attenuates apoptosis and modulates autophagy by targeting TAF9b/P53 pathway in doxorubicin-induced cardiotoxicity[J]. Cell Death Dis, 2019, 10(9): 668.
doi: 10.1038/s41419-019-1901-x
|
[17] |
HULLIN R, MÉTRICH M, SARRE A, et al. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity[J]. Cardiovasc Res, 2018, 114(2): 272-281.
doi: 10.1093/cvr/cvx162
pmid: 29016737
|
[18] |
MUCHIR A, WU W, SERA F, et al. Mitogen-activated protein kinase kinase 1/2 inhibition and angiotensin Ⅱ converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation[J]. Biochem Biophys Res Commun, 2014, 452(4): 958-961.
doi: 10.1016/j.bbrc.2014.09.020
|
[19] |
ZHAN D Y, MORIMOTO S, DU C K, et al. Therapeutic effect of{beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation[J]. Cardiovasc Res, 2009, 84(1): 64-71.
doi: 10.1093/cvr/cvp168
|
[20] |
ZHANG Q L, YANG J J, ZHANG H S. Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy[J]. Biomed Pharmacother, 2019, 109: 71-83.
doi: 10.1016/j.biopha.2018.07.037
|
[21] |
YE Y, GONG H, WANG X X, et al. Combination treatment with antihypertensive agents enhances the effect of qiliqiangxin on chronic pressure overload-induced cardiac hypertrophy and remodeling in male mice[J]. J Cardiovasc Pharmacol, 2015, 65(6): 628-639.
doi: 10.1097/FJC.0000000000000230
pmid: 25806688
|
[22] |
LIPSHULTZ S E, SCULLY R E, LIPSITZ S R, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial[J]. Lancet Oncol, 2010, 11(10): 950-961.
doi: 10.1016/S1470-2045(10)70204-7
pmid: 20850381
|
[23] |
LI M C, SALA V, DE SANTIS M C, et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth[J]. Circulation, 2018, 138(7): 696-711.
doi: 10.1161/CIRCULATIONAHA.117.030352
pmid: 29348263
|
[24] |
PACKER M, MCMURRAY J J, DESAI A S, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure[J]. Circulation, 2015, 131(1): 54-61.
doi: 10.1161/CIRCULATIONAHA.114.013748
pmid: 25403646
|
[25] |
LEVIN E R, GARDNER D G, SAMSON W K. Natriuretic peptides[J]. N Engl J Med, 1998, 339(5): 321-328.
doi: 10.1056/NEJM199807303390507
|
[26] |
MOERTL D, BERGER R, STRUCK J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death[J]. J Am Coll Cardiol, 2009, 53(19): 1783-1790.
doi: 10.1016/j.jacc.2009.01.057
pmid: 19422985
|
[27] |
PONIKOWSKI P, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37(27): 2129-2200.
doi: 10.1093/eurheartj/ehw128
|
[28] |
ZHANG Y S, KNIGHT W, CHEN S, et al. Multiprotein complex with TRPC (transient receptor potential-canonical) channel, PDE1C (phosphodiesterase 1C), and A2R (adenosine A2 receptor) plays a critical role in regulating cardiomyocyte cAMP and survival[J]. Circulation, 2018, 138(18): 1988-2002.
doi: 10.1161/CIRCULATIONAHA.118.034189
pmid: 29871977
|
[29] |
INSEL J, MIRVIS D M, BOLAND M J, et al. A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure[J]. Clin Pharmacol Ther, 1989, 45(3): 312-320.
pmid: 2537699
|
[30] |
COLLABORATION A R B T. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals[J]. J Hypertens, 2011, 29(4): 623-635.
doi: 10.1097/HJH.0b013e328344a7de
|
[31] |
HO C Y, DAY S M, AXELSSON A, et al. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial[J]. Nat Med, 2021, 27(10): 1818-1824.
doi: 10.1038/s41591-021-01505-4
pmid: 34556856
|
[32] |
RURIK J G, TOMBÁCZ I, YADEGARI A, et al. CAR T cells produced in vivo to treat cardiac injury[J]. Science, 2022, 375(6576): 91-96.
doi: 10.1126/science.abm0594
|
[33] |
DESAI A S, MCMURRAY J J, PACKER M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients[J]. Eur Heart J, 2015, 36(30): 1990-1997.
doi: 10.1093/eurheartj/ehv186
pmid: 26022006
|
[34] |
GE Q, ZHAO L, REN X M, et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis[J]. Exp Biol Med (Maywood), 2019, 244(12): 1028-1039.
doi: 10.1177/1535370219861283
pmid: 31262190
|
[35] |
MIZUTA Y, TOKUDA K, GUO J, et al. Sodium thiosulfate prevents doxorubicin-induced DNA damage and apoptosis in cardiomyocytes in mice[J]. Life Sci, 2020, 257: 118074.
doi: 10.1016/j.lfs.2020.118074
|
[36] |
CHILDS A C, PHANEUF S L, DIRKS A J, et al. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio[J]. Cancer Res, 2002, 62(16): 4592-4598.
|
[37] |
MALEK V, GAIKWAD A B. Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy[J]. Cardiovasc Res, 2018, 115(2): 373-384.
doi: 10.1093/cvr/cvy226
|
[38] |
SABBAH H N. Silent disease progression in clinically stable heart failure[J]. Eur J Heart Fail, 2017, 19(4): 469-478.
doi: 10.1002/ejhf.705
pmid: 27976514
|
[39] |
JIA W K, BAI T, ZENG J, et al. Combined administration of metformin and atorvastatin attenuates diabetic cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative stress in type 2 diabetic mice[J]. Front Cell Dev Biol, 2021, 9: 634900.
doi: 10.3389/fcell.2021.634900
|
[40] |
WANG Z Q, CHEN M T, ZHANG R, et al. Docosahexaenoic acid attenuates doxorubicin-induced cytotoxicity and inflammation by suppressing NF-κB/iNOS/NO signaling pathway activation in H9C2 cardiac cells[J]. J Cardiovasc Pharmacol, 2016, 67(4): 283-289.
doi: 10.1097/FJC.0000000000000350
|
[41] |
WANG Y B, LIU L. Effects of carvedilol on myocardial remodeling, oxidative stress, inflammation indexes and endothelial function in hypertensive rats[J]. Minerva Surg, 2021.
|
[42] |
ALANAZI A M, FADDA L, ALHUSAINI A, et al. Liposomal resveratrol and/or carvedilol attenuate doxorubicin-induced cardiotoxicity by modulating inflammation, oxidative stress and S100A1 in rats[J]. Antioxidants (Basel), 2020, 9(2): E159.
|
[43] |
BANGALORE S, KUMAR S, KJELDSEN S E, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials[J]. Lancet Oncol, 2011, 12(1): 65-82.
doi: 10.1016/S1470-2045(10)70260-6
|
[44] |
KEATING G M, JARVIS B. Carvedilol: a review of its use in chronic heart failure[J]. Drugs, 2003, 63(16): 1697-1741.
pmid: 12904089
|
[45] |
SIPAHI I, DEBANNE S M, ROWLAND D Y, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials[J]. Lancet Oncol, 2010, 11(7): 627-636.
doi: 10.1016/S1470-2045(10)70106-6
pmid: 20542468
|